Plain-English translation of NCT05172245 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new drug called combined with the standard chemotherapy and radiation treatment that doctors usually give for advanced head and neck cancer. The goal is to find the right dose of this medication and see if adding it to standard treatment helps patients with head and neck cancer do better. Researchers want to understand whether this medication can help the radiation therapy work more effectively against cancer cells.
Current standard treatment for advanced head and neck cancer uses chemotherapy and radiation, but not all patients respond well or stay cancer-free long-term. Doctors believe this medication might make radiation therapy more effective by targeting a specific pathway in cancer cells, potentially improving survival and quality of life for patients.
You likely qualify if…
You likely don't qualify if…
You would take the study medication by mouth daily or on certain days of the week for two 28-day cycles while receiving standard weekly chemotherapy infusions and daily radiation therapy (Monday through Friday for 7 weeks). You would have regular blood tests and imaging scans to monitor how you're tolerating treatment and how your cancer is responding. After treatment ends, you would have follow-up visits at 6 months and 12 months to check your long-term health, swallowing function, and whether the cancer has returned.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States